Molecular Therapy - Oncolytics

Slides:



Advertisements
Similar presentations
Molecular Therapy - Oncolytics
Advertisements

Volume 15, Issue 6, Pages (June 2007)
Molecular Therapy - Oncolytics
Volume 25, Issue 10, Pages (October 2017)
Molecular Therapy - Methods & Clinical Development
Single Cell-Based Vector Tracing in Patients with ADA-SCID Treated with Stem Cell Gene Therapy  Yuka Igarashi, Toru Uchiyama, Tomoko Minegishi, Sirirat.
Identification of CD3+CD4−CD8− T Cells as Potential Regulatory Cells in an Experimental Murine Model of Graft-Versus-Host Skin Disease (GVHD)  Fumi Miyagawa,
Differentiation of CD4+ T Cells to Th1 Cells Requires MAP Kinase JNK2
Volume 26, Issue 3, Pages (March 2007)
Volume 130, Issue 2, Pages (February 2006)
Volume 134, Issue 1, Pages (January 2008)
miR-150-Mediated Foxo1 Regulation Programs CD8+ T Cell Differentiation
Volume 6, Issue 5, Pages (November 2009)
Volume 25, Issue 3, Pages (March 2017)
Volume 18, Issue 5, Pages (May 2003)
Volume 23, Issue 4, Pages (April 2013)
Volume 26, Issue 2, Pages (February 2018)
Human NK Cell Education by Inhibitory Receptors for MHC Class I
Volume 13, Issue 1, Pages (January 2006)
Volume 42, Issue 3, Pages (March 2015)
Volume 25, Issue 5, Pages (May 2017)
Volume 19, Issue 3, Pages (March 2011)
Volume 26, Issue 4, Pages (April 2018)
Volume 27, Issue 2, Pages (August 2007)
Acquisition of a Functional T Cell Receptor during T Lymphocyte Development Is Enforced by HEB and E2A Transcription Factors  Mary Elizabeth Jones, Yuan.
Volume 36, Issue 6, Pages (June 2012)
Volume 33, Issue 1, Pages (July 2010)
Volume 23, Issue 4, Pages (April 2015)
Molecular Therapy - Methods & Clinical Development
Volume 23, Issue 10, Pages (October 2015)
Molecular Therapy - Oncolytics
Molecular Therapy - Oncolytics
Volume 22, Issue 4, Pages (April 2005)
Alexander Falkenhagen, Sadhna Joshi  Molecular Therapy - Nucleic Acids 
Volume 25, Issue 2, Pages (February 2017)
Volume 24, Issue 9, Pages (September 2016)
Suppression of Murine Colitis and its Associated Cancer by Carcinoembryonic Antigen- Specific Regulatory T Cells  Dan Blat, Ehud Zigmond, Zoya Alteber,
Volume 26, Issue 4, Pages (April 2018)
Skint-1 Identifies a Common Molecular Mechanism for the Development of Interferon-γ- Secreting versus Interleukin-17-Secreting γδ T Cells  Gleb Turchinovich,
Volume 28, Issue 5, Pages (May 2008)
Molecular Therapy - Nucleic Acids
Volume 25, Issue 11, Pages (November 2017)
Molecular Therapy - Oncolytics
Volume 16, Issue 5, Pages (May 2002)
Volume 12, Issue 5, Pages (November 2005)
Volume 26, Issue 2, Pages (February 2018)
Volume 34, Issue 1, Pages (January 2011)
Engineering HIV-Resistant, Anti-HIV Chimeric Antigen Receptor T Cells
Volume 13, Issue 2, Pages (February 2006)
Volume 17, Issue 2, Pages (February 2009)
T Cells with Low Avidity for a Tissue-Restricted Antigen Routinely Evade Central and Peripheral Tolerance and Cause Autoimmunity  Dietmar Zehn, Michael.
Molecular Therapy - Oncolytics
Michael S. Kuhns, Mark M. Davis  Immunity 
Volume 11, Issue 6, Pages (June 2005)
Volume 21, Issue 5, Pages (October 2017)
Molecular Therapy - Oncolytics
Cytotoxic T Lymphocyte Antigen-4 Accumulation in the Immunological Synapse Is Regulated by TCR Signal Strength  Jackson G. Egen, James P. Allison  Immunity 
Volume 24, Issue 6, Pages (June 2016)
Volume 35, Issue 4, Pages (October 2011)
Volume 4, Issue 6, Pages (June 1996)
Volume 20, Issue 3, Pages (March 2012)
Molecular Therapy - Oncolytics
Sindbis Viral Vectors Transiently Deliver Tumor-associated Antigens to Lymph Nodes and Elicit Diversified Antitumor CD8+ T-cell Immunity  Tomer Granot,
Molecular Therapy - Nucleic Acids
Volume 19, Issue 4, Pages (April 2011)
Volume 25, Issue 2, Pages (February 2017)
Volume 23, Issue 4, Pages (April 2015)
Molecular Therapy - Oncolytics
PU.1 Expression Delineates Heterogeneity in Primary Th2 Cells
Volume 2, Issue 6, Pages (December 2012)
Presentation transcript:

Molecular Therapy - Oncolytics HCV T Cell Receptor Chain Modifications to Enhance Expression, Pairing, and Antigen Recognition in T Cells for Adoptive Transfer  Kendra C. Foley, Timothy T. Spear, David C. Murray, Kaoru Nagato, Elizabeth Garrett-Mayer, Michael I. Nishimura  Molecular Therapy - Oncolytics  Volume 5, Pages 105-115 (June 2017) DOI: 10.1016/j.omto.2017.05.004 Copyright © 2017 The Authors Terms and Conditions

Figure 1 Structure of TCRs and Retroviral Vectors (A) Structure of the TCR modifications that were constructed to facilitate pairing. The configuration of the WT TCR has no modifications. DSB TCR introduces another disulfide bond in the constant regions. The murine TCR replaces human constant regions with the corresponding mouse constant regions (hCβ1 to mCβ1 and hCβ2 to mCβ2). The CO TCR allows for efficient translation and an increased rate of protein synthesis. The LZ TCR includes two heterodimerization motifs linked to C terminus of the α and β chains. The SC TCR links the two variable regions with the β constant region, leaving the constant α region as a single domain. (B and C) A modified SAMEN retroviral vector was used to transfer TCR genes to alternate effectors. The retroviral vector contains a splice donor (SD) and splice acceptor (SA), psi (ψ) packaging signal, HCV 1406 TCR alpha (α) and beta (β) chains, and CD34t. The HCV 1406 TCR α and β genes and the CD34t molecule are linked via P2A and T2A sequences, respectively. P2A and T2A are self-cleaving peptides resulting in three separate proteins. CD34t translated into one polypeptide in a 1:1:1 stoichiometric ratio with the TCR α and β genes. It is used as a marker for transduction and to purify transduced cells. NotI, EcoRI, and BamHI restriction sites were used during vector construction. (B) The modified SAMEN retroviral vector used to transfer the WT, DSB, murine, CO, and LZ TCR to effectors. (C) The modified SAMEN retroviral vector used to transfer the SC TCR to effectors. Molecular Therapy - Oncolytics 2017 5, 105-115DOI: (10.1016/j.omto.2017.05.004) Copyright © 2017 The Authors Terms and Conditions

Figure 2 Effect of TCR Pairing Modifications on HCV 1406 TCR Expression Untransduced and HCV 1406 TCR transduced T cells were immunofluorescently stained with anti-CD3 mAb, anti-CD34 mAb, and HCV 1406 dextramer. The log fluorescence was measured by flow cytometry. T cells were gated on CD3+ populations and then analyzed for CD34 and dextramer. Double-positive quadrants represent transduced T cells that also express a properly paired HCV 1406 TCR. Molecular Therapy - Oncolytics 2017 5, 105-115DOI: (10.1016/j.omto.2017.05.004) Copyright © 2017 The Authors Terms and Conditions

Figure 3 Impact of Transduction Efficiency on TCR Pairing The plot above shows the overlapping of fitted lines calculated from the double positive quadrant representing properly paired HCV 1406 TCRs on transduced T cells. Using the compensated log X, Y values from this quadrant for each transduced T cell line, donor, and experiment, fitted lines were plotted as shown above (nine experiments comprising three donors and three repeats). Molecular Therapy - Oncolytics 2017 5, 105-115DOI: (10.1016/j.omto.2017.05.004) Copyright © 2017 The Authors Terms and Conditions

Figure 4 Impact of TCR Pairing Modifications on Specific Antigen Recognition T cells transduced with the WT or modified HCV 1406 TCR were cocultured in a 1:1 ratio with stimulators. IFN-γ release was measured by ELISA. Values represent an average of triplicate wells. One representative experiment and donor is shown (out of nine total experiments). Error bars indicate mean + SEM. Transduced T cell reactivity against T2 cells pulsed with 10 μg/mL HCV NS3:1406-1415 peptide or control tyrosinase:368–376 peptide (top graph) and transduced T cell reactivity against HepG2 and HepG2:NS3+ tumor lines (bottom graph). Molecular Therapy - Oncolytics 2017 5, 105-115DOI: (10.1016/j.omto.2017.05.004) Copyright © 2017 The Authors Terms and Conditions

Figure 5 Effect of TCR Pairing Modifications on Transduced T Cell Polyfunction Antigen reactivity was measured by CD107a and intracellular IFN-γ production. T cells transduced with the WT or modified HCV 1406 TCR were cocultured in a 1:1 ratio with stimulators. One representative experiment and donor is shown (out of nine total experiments). Log fluorescence was measured by flow cytometry and analyzed for surface CD107a and intracellular IFN-γ expression. Collected events were gated on transduced CD4+ and CD8+ T cells. (A) One representative flow cytometry plot presenting poly functional reactivity of transduced CD8+ T cells against T2s targets pulsed with HCV NS3:1406–1415 peptide or control tyrosinase:368–376 peptide. (B–D) Phenotypic percentages of transduced T cells are displayed in pie charts. (B) Transduced CD8+ T cells against peptide loaded T2s. (c) Transduced CD4+ T cells against peptide loaded T2s. (D) Transduced CD8+ T cells against HepG2 and HepG2:NS3+ tumor lines. Molecular Therapy - Oncolytics 2017 5, 105-115DOI: (10.1016/j.omto.2017.05.004) Copyright © 2017 The Authors Terms and Conditions

Figure 6 Impact of Transduction Efficiency on IFN-γ Production by WT or Modified HCV 1406 TCR Transduced T Cells Transduced T cells were stimulated for 5 hr in a 1:1 ratio by T2 cells loaded with HCV 1406 peptide. Immunofluorescence analysis analyzed cells for CD34 and intracellular IFN-γ expression. Collected events were gated on CD8+ T cells. High, medium, and low/none subgates indicate levels of transduction by CD34. One representative experiment and donor is shown (out of nine total experiments). Molecular Therapy - Oncolytics 2017 5, 105-115DOI: (10.1016/j.omto.2017.05.004) Copyright © 2017 The Authors Terms and Conditions

Figure 7 Impact of TCR Pairing Modifications on Structure Changes of the HCV NS3 Peptide JE6.1 cells (with or without CD8+) transduced with the WT, mCβ2, or LZ TCR were cocultured in a 1:1 ratio with T2s pulsed with HCV NS3 alanine-substituted peptides or negative control tyrosinase. IL-2 release was measured by ELISA. Values represent an average of triplicate wells. Error bars indicate mean + SEM. One representative experiment is shown (out of three independent repeats). Molecular Therapy - Oncolytics 2017 5, 105-115DOI: (10.1016/j.omto.2017.05.004) Copyright © 2017 The Authors Terms and Conditions